Cargando…
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
INTRODUCTION: Palmoplantar pustulosis (PPP) is a chronic, inflammatory skin disease, with high disease burden, that is often refractory to treatment. There is a high unmet clinical need for the treatment of patients with PPP. The objectives of this study were to evaluate the safety and efficacy of s...
Autores principales: | Mrowietz, Ulrich, Burden, A. David, Pinter, Andreas, Reich, Kristian, Schäkel, Knut, Baum, Patrick, Datsenko, Yakov, Deng, Hongjie, Padula, Steven J., Thoma, Christian, Bissonnette, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019016/ https://www.ncbi.nlm.nih.gov/pubmed/33661508 http://dx.doi.org/10.1007/s13555-021-00504-0 |
Ejemplares similares
-
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
por: Burden, A. David, et al.
Publicado: (2023) -
Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis
por: Benzian-Olsson, Natashia, et al.
Publicado: (2020) -
Recent advances in palmoplantar pustulosis
por: Brunasso, Alexandra Maria Giovanna, et al.
Publicado: (2021) -
Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
por: Boisvert-Huneault, Christian, et al.
Publicado: (2023) -
Palmoplantar pustulosis and IgA nephropathy
por: Shimamura, Yoshinosuke, et al.
Publicado: (2018)